Biopharma dealmaking continues to rise, but M&A values hold steady: PwC

Thanks to a flurry of dealmaking across the Christmas period and into the new year, it sure feels like both biotechs and Big Pharma have picked up the pace when it comes to hunting down fresh assets. After crunching the data, PwC has come to the same conclusion.

As of May 15, deal volume across the pharma and life sciences sector was up 20% over the previous-year period, according to a mid-year outlook on the U.S. deals scene from the accounting firm. PwC’s analysis is derived from data taken from S&P Capital Market IQ.

“The increase in combined deal volume observed in 2024 continues the robust performance seen in the previous year,” PwC explained to Fierce Biotech via email. “Specifically, there was a 4% uptick in deal volume in 2023 compared to 2022.”

Despite the jump in the number of deals being signed by mid-May to 257—a pattern that…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks